Friday, October 23, 2026

CBOE Is 2% Up In The Last 24 Hours

ViaNews Editorial Team

December 14, 2023

CBOE Is 2% Up In The Last 24 Hours

(VIANEWS) - CBOE (VIX) has been up by 2.65% for the last session's close. At 22:08 EST on Wednesday, 13 December, CBOE (VIX) is $12.39.

CBOE Range

Concerning CBOE's daily highs and lows, it's 4.91% up from its trailing 24 hours low of $11.81 and 2.75% down from its trailing 24 hours high of $12.74.

Concerning CBOE's yearly highs and lows, it's 1.98% up from its 52-week low and 64.65% down from its 52-week high.

Volatility

CBOE's last week, last month's, and last quarter's current intraday variation average was a negative 1.86%, a negative 1.05%, and a positive 4.55%, respectively.

CBOE's highest amplitude of average volatility was 3.34% (last week), 2.32% (last month), and 4.55% (last quarter), respectively.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CBOE's is considered to be overbought (>=80).

News about

  • According to Zacks on Monday, 11 December, "The S&P 500 posted 33 new highs and no new lows while the Nasdaq recorded 104 new highs and 90 new lows.", "The Dow eked out a gain of less than 0.1%, the S&P 500 edged up 0.2% and the Nasdaq increased 0.7%. "
  • According to MarketWatch on Monday, 11 December, "The company has gained 26% in the year to date, outperforming the S&P 500 , which has gained 20%."
  • According to Zacks on Monday, 11 December, "About 98.3% of the medical companies in the S&P 500 have reported earnings so far, and 81.4% of them beat on earnings, while 67.8% surpassed revenue estimates, per Earnings Trends issued on Nov 29, 2023. "
  • According to MarketWatch on Monday, 11 December, "The stock has gained 42% in the year to date, while the S&P 500 has gained 20%."

More news about CBOE (VIX).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Crunch: Late-Stage Readouts and Regulatory Milestones Converge on the Ivonescimab PDUFA Date
October 2026 is dense with clinical and regulatory news. Phase 3 trials hit primary endpoints (ALOFT-IPF, RESTORE-3), long-term data came out (MIUDELLA at 6 years, QUILT-3.032), and the FDA accepted Roche's vamikibart BLA. Scholar Rock resubmitted its apitegromab MAA to the EMA. The next catalysts are ESMO 2026 (Oct 23) and the Nov 14 FDA PDUFA date for ivonescimab, followed by Maritime-1 primary completion in January 2027. The speculative QAIAx items (QIII pilot, microcities patent) are a weak, tangential thread with little financial substance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,426 source documents archived
Query this data → isubstrate.com